Fgfr2 fusions in cholangiocarcinoma

Author: wpfh

August undefined, 2024

WebFGFR2 fusions involve a wide range of fusion partners. 9 To identify patients with FGFR2 fusion-positive cholangiocarcinoma (CCA), it is important to select an assay that: Specifically detects FGFR2 fusions (distinct from FGFR2 point mutations) 16,17 Detects FGFR2 fusions with a wide range of fusion partners 16,17 WebApr 12, 2024 · Given the magnetic resonance imaging findings and positive ctDNA, there was high suspicion of recurrence of a fibroblast growth factor receptor-2 (FGFR2) fusion …

ESMO Congress 2024 OncologyPRO

WebNCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine. WebBackground. FGFR2 fusions/rearrangements (FGFR2 fus) occur in ∼15% of patients (pts) with intrahepatic cholangiocarcinoma (iCCA), a disease with poor outcomes upon progression after 1L standard treatment.Derazantinib is a potent FGFR1-3 kinase inhibitor that has shown broad clinical activity in iCCA pts with FGFR2 fusions, mutations and … tmp kitchen

Outcomes From Second-Line Chemotherapy in Patients with

WebMay 28, 2024 · The FDA has approved infigratinib (Truseltiq) for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement. 1 ... WebAug 1, 2024 · FGFR2 fusion is a biomarker for the diagnosis and therapy of intrahepatic cholangiocarcinoma, so its detection is crucial. In our study, FGFR2 fusion were found in 10.1% of ICC, which is comparable to previous studies [16], [17], [18], [19], [20]. WebBackground Metastatic cholangiocarcinoma (CC), a form of gastrointestinal cancer that originates from the bile ducts, cannot be cured by currently available therapies, and is … tmp law firm

Fibroblast growth factor receptor 2 (FGFR2) fusions in …

WebApr 14, 2024 · Abstract. Background: Fibroblast growth factor receptor (FGFR) alterations are promising targets in different tumors. We report results of FIGHT-207, an … WebApr 13, 2024 · For FGFR2 fusion gene expression analysis, ... Importantly, because most FGFR2 fusion breakpoints in cholangiocarcinoma are patient-specific, most of the … tmp issuesWebApr 12, 2024 · Given the magnetic resonance imaging findings and positive ctDNA, there was high suspicion of recurrence of a fibroblast growth factor receptor-2 (FGFR2) fusion CCA. She tested positive for an FGFR2–AHCYL1 fusion iCCA and is currently on an FGFR inhibitor (pemigatinib) through a clinical trial. Medical oncology perspective tmp low soft

"WebIn iCCA, FGFR2 fusions have been identified as key oncogenic drivers in 10% to 16% of patients 7-9. FGFR2 fusions are found almost exclusively in iCCA.5,8 When they occur, … " - Fgfr2 fusions in cholangiocarcinoma

Fgfr2 fusions in cholangiocarcinoma

Label and Warnings 72730-202 Truseltiq Capsule Oral

WebSep 3, 2024 · Intrahepatic cholangiocarcinoma (iCCA) has emerged as a promising candidate for precision medicine, especially in the case of activating FGFR2 gene fusions. In addition to fusions, a considerable ...

Did you know?

WebApr 12, 2024 · Recently, erdafitinib was approved for the treatment of patients with bladder cancer with FGFR2/3 alterations (fusions and mutations), while futibatinib, infigratinib, and pemigatinib have been approved for the treatment of patients with cholangiocarcinoma with FGFR2 fusions or rearrangements. 1-4 The data derived from these registrational ... WebSep 30, 2024 · The presence of FGFR2 fusions or other rearrangements was determined using next generation sequencing testing. Patients received 20 mg of futibatinib orally once daily until disease progression or ...

WebFeb 10, 2024 · In a clinical study of three patients with FGFR2-fusion cholangiocarcinoma receiving BGJ398 therapy, all patients developed acquired resistance with FGFR2 gatekeeper V564F mutation . In the BaF3 cell line, which has high FGFR2 expression, researchers identified several Dovitinib-resistant mutations, including gatekeeper mutation . WebApr 12, 2024 · Recently, erdafitinib was approved for the treatment of patients with bladder cancer with FGFR2/3 alterations (fusions and mutations), while futibatinib, infigratinib, …

WebFeb 14, 2024 · Histologically or cytologically confirmed, locally advanced, metastatic, or unresectable intrahepatic of extrahepatic Cholangiocarcinoma. Documented evidence … WebOct 19, 2024 · FGFR2 fusions are seen in approximately 10% to 15% of patients with iCCA [and] we’re always looking for new drugs to be available for our patients with cholangiocarcinoma. There are some drugs ...

WebIn recent years, FGFR2 fusions have become one of the most promising targets for precision oncology targeting BTC, with FGFR inhibitors already approved in Europe and the United States for patients with advanced, pretreated iCCA. While the therapeutic potential of nonfusion alterations is still under debate, it is expected that the field of ...

WebApr 1, 2024 · FGFR2 fusions demonstrate transformative potential and oncogenic sensitivity to pemigatinib. A–K: Colony-forming assays for cells transfected with … tmp journal officielWebIn intrahepatic cholangiocarcinoma (iCCA), it may begin with FGFR2 fusion. With next-generation sequencing, it’s now possible to identify clinically significant genomic … tmp line plumbingWebTARGETING FGFR2 FUSIONS IN INTRAHEPATIC CHOLANGIOCARCINOMA Consistent with the nomination of FFs as iCCA drivers, discussed above, several phase II studies in FF+ iCCA patients have shown consistent efficacy for the pan-FGFR inhibitors pemigatinib, infigratinib, debio 1347, derazantinib, and futibatinib ( 37 – 40) ( Table 1 ). tmp lightingWebJan 19, 2024 · 427 Background: Derazantinib, a potent anti- FGFR1-3 oral kinase inhibitor, has shown clinically meaningful anti-tumor activity (21%), durable responses (median, 6.4 months), and progression-free survival (median, 8.0 months) in patients (pts) with FGFR2 fusion (FGFR2F)-positive intrahepatic cholangiocarcinoma (iCCA), and with a … tmp marian football madnessWebEfficacy was demonstrated in CBGJ398X2204 (NCT02150967), a multicenter open-label single-arm trial, that enrolled 108 patients with previously treated, unresectable locally … tmp lightWebJan 27, 2024 · In recent years, FGFR2 fusions have become one of the most promising targets for precision oncology targeting BTC, with FGFR inhibitors already approved … tmp log thermometerWebFGFR2 fusions and rearrangements occurring in 10–16% of patients with intrahepatic cholangiocarcinoma (ICC) reported in published scientific literature. Pemigatinib, a selective FGFR inhibitor, has demonstrated the high therapeutic potentials for ICC patients with FGFR2 fusions or rearrangements, according to the results of FIGHT 202 study. tmp mechanical